Ikarian Capital has $17 million worth of CALL options in AstraZeneca PLC (NASDAQ: AZN) of the end of the first quarter. On July 21, Citi analyst Andrew Baum raised the price target on AstraZeneca PLC (NASDAQ: AZN) to 10,500 GBp from 10,000 GBp and reiterated a "Buy" rating on the shares.